Rabin SABA, Ata Nevzat YALÇIN, Filiz GÜNSEREN, Latife MAMIKOĞLU, Dilara İNAN, Özge TURHAN

Surveillance of antimicrobial use in a Turkish university hospital

To determine antimicrobial use in a university hospital in Turkey and compare it with United States antimicrobial use and resistance (US-AUR) and International Nosocomial Infection Control Consortium (INICC) rates. Materials and methods: This was a prospective surveillance study done between January 2007 and December 2007. The data are standardized by use of the defined daily dose (DDD) for each antimicrobial group and by calculating use per 1000 patients (antibiotic use density-AD). Results: Data on 35,936 patients with a total of 215,616 patient-days were analyzed. Ampicillin group (mainly with a beta lactamase inhibitor) has the highest AD in ICU and non-ICU departments (AD was 308 and 244 DDD/1000 patient day, respectively). Compared with the US-AUR rates ADs for ampicillin group, antipseudomonal penicillin group, 1st generation cephalosporins and carbapenems were over the 75th percentile for almost all types of ICU. Fluoroquinolones AD was below the 10th percentile at most ICUs. Inversely compared with INICC data, none of antimicrobial group exceeded the 90th percentile for all ICUs. There was a statistically significant (P < 0.01) correlation between incidence densities of all nosocomial infections and ventilator utilization rate with the use of antipseudomonal penicillins, 3rd generation cephalosporins, carbapenems, and glycopeptides at ICUs. Conclusion: We found a positive correlation with nosocomial infections densities and the use of broad spectrum antimicrobials in ICUs. To use antimicrobials wisely we must implement a comprehensive education program together with infection control measures. A national program for antimicrobial usage may provide more precise data for inter-hospital comparisons.

Anahtar Kelimeler:

Key words: Antibiotic surveillance, daily defined dose

Surveillance of antimicrobial use in a Turkish university hospital

Keywords:

Key words: Antibiotic surveillance, daily defined dose,

PDF

___

1. Pinner RW, Teutsch SM, Simonsen L Klug LA, Graber JM, Clarke MJ et al. Trends in infectious diseases mortality in the United states. JAMA 1996; 275: 189-193.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 47-485.
3. Rosenthal VD, Maki DG, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F et al. International Nosocomial Infection Control Consortium Members. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008; 36: 627-37.
4. World Health Organization: WHO global strategy for containment of antimicrobial resistance. 2001 WHO/CDS/ CSR/DRS/2001.2.
5. Anonymous. Proposal for a council recommendation on the prudent use of antimicrobial agents in human medicine. Offi cial Journal of the European Communities L 2001; 34/13: 13502-13501.
6. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245–252.
7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC defi nitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140.
8. Borg MA, Zarb P, Ferech M, Goossens H; ARMed Project Group. Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project. J Antimicrob Chemother 2008; 62: 830-836.
9. Hanberger H, Arman D, Gill H, Jindrák V, Kalenic S, Kurcz A et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med. 2009; 35: 91-100.
10. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30: 1089-1096.
11. Inan D, Saba R, Gunseren F Ongut G, Turhan O, Yalcin AN et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis. 2005; 5: 5.
12. Gaynes R. Th e impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11: 757-765.
13. Bratzler DW, Houck PM. Surgical infection prevention guideline writers workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005; 189: 395-404.
14. Inan D, Saba R, Yalcin AN Yilmaz M, Ongut G, Ramazanoglu A et al. Device-associated nosocomial infection rates in Turkish medical-surgical intensive care units. Infect Control Hosp Epidemiol 2006; 27: 343-348.
15. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection 2003; 31: 208-215.
16. Walther SM, Erlandsson M, Burman LG Cars O, Gill H, Hoff man M et al. Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46: 1075-1081